TCL Archive Four Patients In Tamoxifin Treatment Trial Had Died of Uterine Cancer Prior To BCPT April 29, 1994
TCL Archive CCIRC Fears Multimodality Studies Threatened By Cooperative Groups’ Misapplication Of Funds January 14, 1977
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
